Clinical Effectiveness and Pharmacokinetics of Dalbavancin in Treatment-Experienced Patients with Skin, Osteoarticular, or Vascular Infections

• Main Authors: Giacomo Stroffolini (Author), Amedeo De Nicolò (Author), Alberto Gaviraghi (Author), Jacopo Mula (Author), Giuseppe Cariti (Author), Silvia Scabini (Author), Alessandra Manca (Author), Jessica Cusato (Author), Silvia Corcione (Author), Stefano Bonora (Author), Giovanni Di Perri (Author), Francesco Giuseppe De Rosa (Author), Antonio D'Avolio (Author)
• Format: Book
• Published: MDPI AG, 2022-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Dalbavancin (DBV) is a lipoglycopeptide approved for the treatment of Gram-positive infections of the skin and skin-associated structures (ABSSSIs). Currently, its off-label use at different dosages for other infections deserves attention. This work aimed to study the clinical effectiveness and tole...